The Eppley Seminar Series on Thursday, February 12^th at 10:00am will feature Dr. Joyce Solheim. (Rescheduled from Jan. 15th.)

Presentation title: "Histone Deacetylase Inhibition as a Strategy to Complement Cancer Chemotherapy"

• The histone deacetylase (HDAC) inhibitor M344 was demonstrated not to be more toxic to non-malignant cells than an FDA-approved HDAC inhibitor.
• M344 plus a standard chemotherapy for pancreatic cancer (gemcitabine) reduced pancreatic cancer cell proliferation more than either M344 or gemcitabine used as solo therapies.
• In a mouse model of neuroblastoma, M344 was shown to increase the tolerability of topotecan therapy, and M344 coupled with cyclophosphamide suppressed tumor growth rebound better than cyclophosphamide alone.

We hope to see you there!